ArticleNPJ Parkinson's disease2018

Safety and tolerability of IRL790 in Parkinson's disease with levodopa-induced dyskinesia-a phase 1b trial.

Per Svenningsson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.